A case of a female patient with hair loss induced by coronavirus dis-ease 2019 (COVID-19) vaccination who was treated with autologous CD34+ enriched hematopoietic progenitor cell fraction (CD34+ HPCF) and umbilical cord blood-derived mesenchymal stem cells (UC-MSCs) was reported. The patient presented with generalized pain and hair loss after COVID-19 vaccination. The patient received subcutaneous injec-tions of autologous CD34+ HPCF at 1-cm intervals into the scalp. These injections were administered once a week for a total of 10 times, except in weeks 5 and 10. During this period, UC-MSCs were administered in-travenously at dose of 7×107 cells in 20 mL and subcutaneously at a dose of 1×107 cells in 5 mL into the scalp twice each in weeks 5 and 10. After 12 weeks of treatment, the patient’s hair loss improved without significant adverse effects. Autologous CD34+ HPCF and UC-MSC in-jections showed significant effects on hair loss induced by COVID-19 vaccination.
Suyeon Kim (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: